Meaghan Beattie

Dr. Meaghan Beattie

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2016 in Pediatric Cardiology
Verified
Journal Article
Closed access
PDF file
MBMeaghan Beattie
Meaghan Beattie
SPShabnam Peyvandi
Shabnam Peyvandi
SGSuguna Ganesan
Suguna Ganesan
AMAnita Moon-Grady
Anita Moon-Grady

1 August 2023 in Circulation: Genomic and Precision Medicine
Verified
Journal Article
Open access
EMEmanuele Monda
Emanuele Monda
APAaron Prosnitz
Aaron Prosnitz
RARossella Aiello
Rossella Aiello
MLMichele Lioncino
Michele Lioncino
GNGabrielle Norrish
Gabrielle Norrish
Giuseppe LimongelliGiuseppe Limongelli
Giuseppe Limongelli
BACKGROUND: We aimed to examine clinical features and outcomes of consecutive molecularly characterized patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy. METHODS: A retrospective, longitudinal multicenter cohort of consecutive children and adults with a genetic diagnosis of Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy between 2002 and 2019 was assembled. We defined a priori 3 different patterns of left ventricular remodeling during follow-up: (1) an increase in ≥15% of the maximal left ventricular wall thickness (MLVWT), both in mm and z -score (progression); (2) a reduction ≥15% of the MLVWT, both in mm and z -score (absolute regression); (3) a reduction ≥15% of the MLVWT z -score with a stable MLVWT in mm (relative regression). The primary study end point was a composite of cardiovascular death, heart transplantation, and appropriate implantable cardioverter defibrillator-shock. RESULTS: The cohort comprised 42 patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy, with a median age at diagnosis of 3.5 (interquartile range, 0.2–12.3) years. Freedom from primary end point was 92.7% (95% CI, 84.7%–100%) 1 year after presentation and 80.9% (95% CI, 70.1%–90.7%) at 5 years. Patients with MLVWT z -score >13.7 showed reduced survival compared with those with <13.7. During a median follow-up of 3.7 years (interquartile range, 2.6–7.9), absolute regression was the most common type of left ventricular remodeling (n=9, 31%), followed by progression (n=6, 21%), and relative regression (n=6, 21%). CONCLUSIONS: These findings provide insights into the natural history of left ventricular hypertrophy, and can help inform clinicians regarding risk stratification and clinical outcomes in patients with Noonan syndrome with multiple lentigines and hypertrophic cardiomyopathy.

23 January 2023 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
MBMeaghan Beattie
Meaghan Beattie
LSLynn A. Sleeper
Lynn A. Sleeper
MLMinmin Lu
Minmin Lu
STSarah A. Teele
Sarah A. Teele
RBRoger E. Breitbart
Roger E. Breitbart
PBPuja Banka
Puja Banka

18 January 2021 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
MBMeaghan Beattie
Meaghan Beattie
KFKevin G. Friedman
Kevin G. Friedman
LSLynn A. Sleeper
Lynn A. Sleeper
MLMinmin Lu
Minmin Lu
MDMonika Drogosz
Monika Drogosz
WTWayne Tworetzky
Wayne Tworetzky

13 October 2023 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
HCHamsika Chandrasekar
Hamsika Chandrasekar
BKBeth D. Kaufman
Beth D. Kaufman
MBMeaghan Beattie
Meaghan Beattie
DEDaniel Bruce Ennis
Daniel Bruce Ennis
ASAli B Syed
Ali B Syed
SMShiraz A Maskatia
Shiraz A Maskatia